85 related articles for article (PubMed ID: 20081767)
21. Refining stent technologies for femoral interventions.
Bosiers M; Deloose K; Callaert J; Maene L; Keirse K; Verbist J; Peeters P
J Cardiovasc Surg (Torino); 2012 Aug; 53(4):465-73. PubMed ID: 22854526
[TBL] [Abstract][Full Text] [Related]
22. A budget impact model for paclitaxel-eluting stent in femoropopliteal disease in France.
De Cock E; Sapoval M; Julia P; de Lissovoy G; Lopes S
Cardiovasc Intervent Radiol; 2013 Apr; 36(2):362-70. PubMed ID: 23073560
[TBL] [Abstract][Full Text] [Related]
23. Drug-eluting stents for the treatment of complex femoro-popliteal disease: a systematic review and meta-analysis.
Katsogridakis E; Ballance L; Cawley O; Antoniou GA
J Cardiovasc Surg (Torino); 2022 Jun; 63(3):299-307. PubMed ID: 30168308
[TBL] [Abstract][Full Text] [Related]
24. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
25. Early results with the use of heparin-bonded stent graft to rescue failed angioplasty of chronic femoropopliteal occlusive lesions: TASC D lesions have a poor outcome.
Kuhan G; Abisi S; Braithwaite BD; MacSweeney ST; Whitaker SC; Habib SB
Cardiovasc Intervent Radiol; 2012 Oct; 35(5):1023-8. PubMed ID: 22696009
[TBL] [Abstract][Full Text] [Related]
26. Peripheral drug-eluting technology.
Franzone A; Stabile E; Trimarco B; Esposito G
Cardiol Clin; 2015 Feb; 33(1):151-62. PubMed ID: 25439337
[TBL] [Abstract][Full Text] [Related]
27. Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia.
Martens JM; Knippenberg B; Vos JA; de Vries JP; Hansen BE; van Overhagen H;
J Vasc Surg; 2009 Sep; 50(3):687-9. PubMed ID: 19700099
[TBL] [Abstract][Full Text] [Related]
28. Stenting vs above knee polytetrafluoroethylene bypass for TransAtlantic Inter-Society Consensus-II C and D superficial femoral artery disease.
Dosluoglu HH; Cherr GS; Lall P; Harris LM; Dryjski ML
J Vasc Surg; 2008 Nov; 48(5):1166-74. PubMed ID: 18692357
[TBL] [Abstract][Full Text] [Related]
29. First- and second-generation drug-eluting balloons for femoro-popliteal arterial obstructions: update of technique and results.
De Vries JP; Karimi A; Fioole B; Van Leersum M; Werson DA; Van Den Heuvel DA
J Cardiovasc Surg (Torino); 2013 Jun; 54(3):327-32. PubMed ID: 23640355
[TBL] [Abstract][Full Text] [Related]
30. Drug eluting stents in the treatment of below the knee arterial occlusive disease.
Varcoe RL
J Cardiovasc Surg (Torino); 2013 Jun; 54(3):313-25. PubMed ID: 23640354
[TBL] [Abstract][Full Text] [Related]
31. Drug-eluting stents below the knee.
Bosiers M; Deloose K; Callaert J; Keirse K; Verbist J; Peeters P
J Cardiovasc Surg (Torino); 2011 Apr; 52(2):231-4. PubMed ID: 21460773
[TBL] [Abstract][Full Text] [Related]
32. Drug-eluting stents in the management of peripheral arterial disease.
Bosiers M; Cagiannos C; Deloose K; Verbist J; Peeters P
Vasc Health Risk Manag; 2008; 4(3):553-9. PubMed ID: 18827906
[TBL] [Abstract][Full Text] [Related]
33. Prevention and treatment of in-stent restenosis.
Bosiers M; Deloose K; Keirs K; Verbist J; Peeters P
J Cardiovasc Surg (Torino); 2010 Aug; 51(4):591-8. PubMed ID: 20671644
[TBL] [Abstract][Full Text] [Related]
34. Late peripheral stent thrombosis due to stent fracture, vigorous exercise and hyporesponsiveness to clopidogrel.
Linnemann B; Thalhammer A; Wolf Z; Tirneci V; Vogl TJ; Edelgard Lindhoff-Last A
Vasa; 2012 Mar; 41(2):136-44. PubMed ID: 22403133
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes of the SMART stent in femoro-popliteal disease in TASC A/B lesions and TASC C/D lesions.
Echeverria A; Krajcer Z
Catheter Cardiovasc Interv; 2016 Nov; 88(5):841-842. PubMed ID: 27865072
[No Abstract] [Full Text] [Related]
36. Commentary: All That Glitters Is Not Zilver: Promises and Disappointments of Endovascular Devices for Superficial Femoral Artery Disease.
Gatto L; Frati G; Biondi-Zoccai G; Giordano A
J Endovasc Ther; 2018 Jun; 25(3):302-305. PubMed ID: 29673300
[No Abstract] [Full Text] [Related]
37. For which peripheral lesions could we consider drug eluting stents?
Tessarek J
J Cardiovasc Surg (Torino); 2016 Apr; 57(2):257-65. PubMed ID: 26675837
[TBL] [Abstract][Full Text] [Related]
38. Drug Eluting Stents in Infrapopliteal Arterial Disease: A Pilot Safety Study in an Asian Population.
Damodharan K; Patel A; Irani FG; Burgmans MC; Gogna A; Tay KH; Lo RH; Too CW; Leong S; Venkatanarasimha N; Chan S; Win HH; Sivanathan C; Tan BS
Ann Acad Med Singap; 2017 Apr; 46(4):155-159. PubMed ID: 28485463
[No Abstract] [Full Text] [Related]
39. A magic tool for CTO or another piece of junk.
Yokoi Y
Catheter Cardiovasc Interv; 2010 Nov; 76(5):740. PubMed ID: 20976756
[No Abstract] [Full Text] [Related]
40. Clinical results using the direct stent puncture technique to treat SFA in-stent occlusion.
Manzi M; Palena LM; Brocco E
J Endovasc Ther; 2012 Jun; 19(3):461-2. PubMed ID: 22788902
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
